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Cancer Guideline Harmonization Group in collaboration with 
the PanCareSurFup Consortium
Roderick Skinner, Renee L Mulder, Leontien C Kremer, Melissa M Hudson, Louis S Constine, Edit Bardi, Annelies Boekhout, Anja Borgmann-Staudt, 
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Lilian Meacham, Sebastian Neggers, Stephen Nussey, Cecilia Petersen, Margarett Shnorhavorian, Marry M van den Heuvel-Eibrink, 
Hanneke M van Santen, William H B Wallace, Daniel M Green
Treatment with chemotherapy, radiotherapy, or surgery that involves reproductive organs can cause impaired 
spermatogenesis, testosterone deﬁ ciency, and physical sexual dysfunction in male pubertal, adolescent, and young 
adult cancer survivors. Guidelines for surveillance and management of potential adverse eﬀ ects could improve cancer 
survivors’ health and quality of life. Surveillance recommendations vary considerably, causing uncertainty about 
optimum screening practices. This clinical practice g uideline recommended by the International Late Eﬀ ects of 
Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium, developed 
using evidence-based methodology, critically synthesises surveillance recommendations for gonadotoxicity in male 
childhood, adolescent, and young adult (CAYA) cancer survivors. The recommendations were developed by an 
international multidisciplinary panel including 25 experts in relevant medical specialties, using a  consistent and 
transparent process. Recommendations were graded according to the strength of underlying evidence and potential 
beneﬁ t gained by early detection and appropriate management. The aim  of the recommendations is to enhance 
evidence-based care for male CAYA cancer survivors. The guidelines reveal the paucity of high-quality evidence, 
highlighting the need for further targeted research.
Introduction
Advances in the treatment of childhood, adolescent, and 
young adult (CAYA) cancer have led to 5-year survival 
exceeding 80%.1,2 Unfortunately, many CAYA cancer 
survivors experience long-term morb idity and mortality 
resulting from cancer, treatment, or both.3,4 The risk of 
treatment-induced gonadotoxicity often causes emotional 
distress for male survivors5–10  and impaired spermato-
genesis results in reduced or lost fertility.5,7 Testosterone 
deﬁ ciency causes delayed or arrested puberty in 
adolescents, and many adverse somatic and psychological 
consequences in adults.6,8,11,12 Sexual dysfunction can have 
both phys ical and psychosexual consequences.10,13
Male survivors at risk of cancer and treatment-related 
gonadotoxic eﬀ ects and their health-care providers could 
beneﬁ t from clinical practice guidelines to facilitate 
timely remedial or health-preserving interventions.14–17 
P ublished clinical practice guidelines developed by 
North American and European groups for long-term 
follow-up of CAYA cancer survivors18–21 vary  in deﬁ nitions 
of at-risk populations and recommendations for 
treatment modalities and frequency of surveillance. 
Because diﬀ erences in published guidelines  might 
hinder guideline implementation and provision of 
consistent clinically eﬀ ective care, the International Late 
Eﬀ ects of Childhood Cancer Guideline Harmonization 
Group (IGHG) was developed  to critically examine 
the evidence and harmonise existing long-term 
follow-up guidelines.22 The European Union-funded 
PanCareSurFup (PCSF) Consortium collaborated with 
IGHG to identify treatments associated with increased 
risk of impaired spermatogenesis, testosterone 
deﬁ ciency, and physical sexual dysfunction in male 
CAYA cancer survivors, and evaluate surveillance 
strategies. This Review summarises the evidence and 
recommendations. Treatment of impaired sperma to-
genesis, testosterone deﬁ ciency and physical sexual 
dysfunction by relevant specialist clinicians was not 
included in this Review.
Aim of the study
IGHG’s aims and methodology have been published.22 
Guideline representatives from the North American 
Children’s Oncology Group (COG),19 Dutch Childhood 
Oncology Group (DCOG), Scottish Intercollegiate 
Guidelines Network (SIGN),20 United Kingdom 
Children’s Cancer and Leukaemia Group (CCLG),18 PCSF 
Consortium,23 and other international paediatric onco-
logy societies developed a working group of 25 experts 
from nine countries, selected for their knowledge of and 
publications in paediatric (four members) or adult 
endocrinology (two members), andrology (one member), 
paediatric, adolescent haema tology, oncology, or 
long-term follow-up (twelve members), urology 
(one member), radiation oncology (one member), 
psychology (one member), and epidemiology and 
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guideline methodology (three members). The group 
worked together via web conferences, face-to-face 
meetings, and email correspondence.
The experts looked for areas of concordance and 
discordance across the COG, DCOG, SIGN, and CCLG 
guidelines. They devised clinical questions to address 
areas of discordance for surveillance of impaired 
spermatogenesis, testosterone deﬁ ciency, and physical 
limitations that lead to sexual dysfunction (subsequently 
described as physical sexual dysfunction) covering the 
following key issues: who needs surveillance; which 
surveillance modality should be used; how often and 
for how long surveillance should be performed; and 
when survivors should be referred (appendix pp 1–3).
Methods
We did systematic searches in the medical literature for 
studies of CAYA survivors (see appendix, pp 4–10, for more 
details).
Search strategy and selection criteria
Systematic literature searches were performed between 
January, 1993 and October, 2014 (appendix, pp 4–10). We 
searched MEDLINE (through PubMed) using the search 
terms “childhood cancer”, “male”, “alkylating agents”, 
“platinum agents”, “radiotherapy”, “orchidectomy”, 
“impaired spermatogenesis”, “testosterone deﬁ ciency”, 
“sexual dysfunction”, “FSH”, “inhibin B”, “LH”, 
“testosterone” (detailed search strategies are provided in 
the appendix, pp 4–10). We critiqued references 
supporting the existing recommendations and contacted 
experts in the specialty to determine if any additional 
evidence was available. Only reports published in English 
were reviewed. The inclusion criteria were based on 
study population, outcomes, type, and date of study. 
Eligible study populations were male human childhood, 
adolescent, and young adult cancer survivors, in which 
75% or more had been diagnosed with cancer before the 
age of 25 years and 50% or more had been followed up 
for 2 years or more after cancer diagnosis. Eligible study 
outcomes were impaired spermatogenesis (azoospermia, 
oligozospermia) or testosterone deﬁ ciency. All study 
designs were eligible (including diagnostic studies to 
address which surveillance modality should be used) if 
the sample size included 20 patients or more and if the 
study controlled for important confounding factors, such 
as treatment or age (eg, cohort study using a multivariable 
or multiple regression analysis or case control study that 
used measures to control for important factors). Studies 
that used only a univariable analysis were excluded. 
Studies published from 1993 onwards were eligible.
Studies meeting the inclusion criteria were selected 
and evidence summaries were generated to answer the 
clinical questions. The ﬁ nal selection of studies was 
based on relevance to the broad scope of this guideline. 
In the case of concordance, the evidence cited by the 
guidelines was evaluated.
Papers were selected for evidence summaries if they 
reported a primary outcome. Conclusions based on 
gonado trophins alone were not used to inform surveillance 
recommendations for impaired spermato genesis or 
testosterone deﬁ ciency because they were not deﬁ ned as 
primary outcomes and patients treated with cranial 
radiotherapy might develop hypogonadotropic hypo-
gonadism, and hence blunted gonadotrophin responses.
Studies of surveillance modalities for impaired 
spermatogenesis calculated the area under the curve 
(AUC) of the receiver operating characteristics (ROC) 
curves to evaluate accuracy of a diagnostic investigation. 
We used Tape’s criteria,24 based on the numerical value of 
the AUC of the ROC curve, to analyse the diagnostic 
value of investigations.
In cases whereby no or only low-quality evidence was 
identiﬁ ed for the gonadotoxic eﬀ ect (or absence) of a 
treatment, relevant information was extrapolated from 
studies that did not meet the systematic search’s 
eligibility criteria, including studies published before 
1993. Conclusions from this supplemental search were 
agreed upon and described as reﬂ ecting expert opinion. 
They were categorised as probably demonstrating an 
eﬀ ect or no eﬀ ect of the treatment, or as suggesting that 
the risk was unclear. For a full ﬂ owcharton the studies 
selected see ﬁ gure 1.
Deﬁ nitions used
Given the heterogeneity in deﬁ nitions of relevant 
therapeutic exposures, surveillance strategies and clinical 
outcomes, we developed standardised deﬁ nitions for our 
literature review and ﬁ nal recommendations.
CAYA cancer survivors were deﬁ ned as individuals 
diagnosed with cancer up to 25 years of age and at least 
2 years after completion of treatment, regardless of 
current age.
Chemotherapy drugs included in the literature searches 
were alkylating and similar DNA interstrand cross-
linking agents, including bifunctional classical alkylators 
(busulfan, chlorambucil, cyclophosphamide, ifosfamide, 
chlormethine, melphalan, thiotepa), platinum agents 
(carboplatin, cisplatin), and monofunctional nitrosoureas 
(carmustine, lomustine), and triazenes (dacarbazine, 
procarbazine, temozolomide). These drugs are 
subsequently referred to collectively as alkylating agents. 
Cytarabine was also included in view of reports of 
potential gonadotoxicity.25,26
Radiotherapy potentially exposing the testes or pelvis 
included the following treatment volumes: testes, ﬂ ank 
or hemi-abdomen if the radiotherapy ﬁ eld extended 
below the iliac crest, whole abdomen, inverted Y (para-
aortic, iliac, inguinal, and upper femoral lymph nodes, 
often with spleen or splenic pedicle), pelvis, prostate, 
bladder, iliac, inguinal, femoral, thigh, total lymphoid 
irradiation, total nodal irradiation, and total body 
irradiation (TBI). Although radiotherapy (eg, cranial) that 
potentially exposes the hypothalamic–pituitary region 
Australia (Prof R Cohn FRACP); 
Department of Paediatric 
Haematology and Oncology, 
University Hospital Muenster, 
Muenster, Germany 
(Prof U Dirksen MD); Department 
of Translational Medicine, Lund 
University, Malmö, Sweden 
(Prof A Giwercman MD); 
Department of Pediatrics, Tokai 
University School of Medicine, 
Isehara, Japan (H Ishiguro MD); 
Division of 
Hematology-Oncology and 
Stem Cell Transplantation, 
Children’s Hospital, University of 
Helsinki and Helsinki University 
Hospital, Helsinki, Finland 
(K Jahnukainen PhD); Department 
of Pediatric Oncology, Dana-
Farber/Boston Children’s Cancer 
and Blood Disorder Center, 
Harvard Medical School, Boston, 
MA, USA (Prof L B Kenney MD); 
Department of Hematology, 
Radboud University Medical 
Center, Nijmegen, Netherlands 
(J J Loonen PhD); Department of 
Pediatrics, Division of 
Hematology/ Oncology and 
Endocrinology, Emory University 
and Aflac Cancer Center of 
Children’s Healthcare of Atlanta, 
Atlanta, GA, USA 
(Prof L Meacham MD); 
Department of Medicine section 
Endocrinology, Erasmus 
University Medical Center 
Rotterdam and Pediatric 
Oncology, Sophia’s Children’s 
Hospital/Erasmus University 
Medical Center, Rotterdam, 
Netherlands (S Neggers PhD); 
Department of Endocrinology, 
St George’s University of 
London, London, UK 
(Prof S Nussey DPhil); 
Department of Pediatric 
Oncology, Karolinska University 
Hospital, Stockholm, Sweden 
(C Peterson PhD); Department of 
Urology, University of 
Washington, Division of 
Pediatric Urology, Seattle 
Children’s Hospital, Seattle, WA, 
USA (M Shnorhavorian MD); 
Princess Maxima Center for 
Pediatric Oncology, Utrecht, 
Netherlands 
(Prof M M van den Heuvel-Eibrink 
MD); Department of Pediatric 
Endocrinology, Wilhelmina 
Kinderziekenhuis, Universitair 
Medisch Centrum Utrecht, 
Utrecht, Netherlands 
(H M van Santen MD); and 
University of Edinburgh and 
Royal Hospital for Sick Children, 
Edinburgh, UK 
(Prof W H B Wallace MD)
www.thelancet.com/oncology   Vol 18   February 2017 e77
Review
might cause central hypogonadism and was included in 
our search strategy, we did not develop surveillance 
recommendations because this will be evaluated in a 
future IGHG/PCSF pituitary dysfunction guideline.
Primary and other outcomes were deﬁ ned. For primary 
outcomes, impaired spermatogenesis was deﬁ ned as 
azoospermia or oligozoospermia demonstrated by semen 
analysis, testosterone deﬁ ciency as decreased serum 
testosterone concentrations, and physical sexual 
dys function as erectile or ejaculatory dysfunction, or 
impotence. Reference ranges were the same as those 
used in the selected articles. Other outcomes evaluated 
included elevated serum follicle-stimulating hormone 
(FSH), or reduced serum inhibin B concentration (for 
impaired spermatogenesis), and elevated serum 
luteinising hormone (LH) concentration (for testosterone 
deﬁ ciency). Delayed puberty was deﬁ ned as failure to 
develop signs of puberty by 14 years of age. Failure of 
pubertal progression was deﬁ ned as no change in 
pubertal stage for at least 6 months at the age at which 
progression would be expected.
Final recommendations
Final recommendations were based on scientiﬁ c 
knowledge in the evidence summaries, combined with 
other considerations including clinical judgements, 
decisions about thresholds, costs, potential harms from 
excessive screening, and the need to maintain ﬂ exibility 
of application across diﬀ erent health-care systems. The 
quality of the evidence and the strength of the 
recommendations were graded according to published 
evidence-based methods (appendix pp 11–12).22,27,28 
The harmonised male gonadotoxicity surveillance 
recommendations were critically appraised by two 
independent external experts in the ﬁ eld and ﬁ ve survivor 
representatives.
Findings
Tables 1–3 show the concordances and discordances 
between existing surveillance recommendations for 
impaired spermatogenesis, testosterone deﬁ ciency, and 
physical sexual dysfunction.
Many areas of discordance were identiﬁ ed that required 
more detailed investigation of the evidence. The appendix 
presents the clinical questions (pp 1–3), evidence 
summaries (pp 13–34), and conclusions of evidence 
tables (pp 35–48) for the evidence summaries, and 
summarises evidence from and provides references for 
studies identiﬁ ed by the supplemental search (pp 49–53).
Of 3202 studies of impaired spermatogenesis, 
testosterone deﬁ ciency, and physical sexual dysfunction 
identiﬁ ed, seven met all inclusion criteria to address who 
needs surveillance and at what frequency (ﬁ gure 1A). Of 
1170 studies of impaired spermatogenesis and 
testosterone deﬁ ciency identiﬁ ed, six met all inclusion 
criteria to address which surveillance modality should be 
used (ﬁ gure 1B).
Impaired spermatogenesis 
Who needs surveillance? 
The existing surveillance recommendations were 
discordant about which chemotherapy, radiotherapy, and 
surgery exposures place CAYA cancer survivors at risk of 
impaired spermatogenesis.
We found that cyclophosphamide and the combin-
ation of chlormethine and procarbazine have been 
associated with increased risk of impaired 
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3202 potentially relevant studies identiﬁed 
 by the PubMed search 1993–2014
2908 excluded on basis of title and abstract
294 retrieved in full text for more detailed 
 examination
61 additional articles retrieved after hand 
 searching reviews and existing guidelines
348 excluded (did not meet inclusion criteria)
7 met all inclusion criteria
 4 impaired spermatogenesis
 3 testosterone deﬁciency
 0 physical sexual dysfunction
A
1170 potentially relevant studies identiﬁed 
 by the PubMed search 1993–2014
1100 excluded on basis of title and abstract
70 retrieved in full text for more detailed 
 examination
57 additional articles retrieved after hand 
 searching reviews and existing guidelines
121 excluded (did not meet inclusion criteria)
6 met all inclusion criteria
 6 impaired spermatogenesis
 0 testosterone deﬁciency
B
Figure 1: Selection of studies
(A) Studies of impaired spermatogenesis, testosterone deﬁ ciency, and physical 
sexual dysfunction were selected to address who needs surveillance and at what 
frequency. (B) Studies of impaired spermatogenesis and testosterone deﬁ ciency 
were selected to address which surveillance modality should be used.
For more on Cochrane 
Childhood Cancer see http://ccg.
cochrane.org
e78 www.thelancet.com/oncology   Vol 18   February 2017
Review












Who needs impaired spermatogenesis surveillance?
At risk All survivors
Alkylating agents* Yes Not speciﬁ ed Yes Yes Discordant
Procarbazine Yes Not speciﬁ ed Yes Not speciﬁ ed Discordant
Temozolamide, dacarbazine Yes Not speciﬁ ed Yes Not speciﬁ ed Discordant
Carboplatin, cisplatin Yes Not speciﬁ ed Yes Not speciﬁ ed Discordant
Cytarabine Not speciﬁ ed Not speciﬁ ed Yes Not speciﬁ ed Discordant
Radiotherapy exposing testes† Yes Not speciﬁ ed Yes Yes Discordant
Unilateral orchiectomy Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Highest risk
Higher doses alkylating agents Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Alkylating agent dose MOPP 3 cycles or more
Busulfan (≥600 mg/m²)
Cyclophosphamide (≥7·5 g/m²) 
Cyclophosphamide for HSCT
Ifosfamide (≥60 g/m²)
Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Combination alkylating agents Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Higher dose radiotherapy exposing testes Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Radiotherapy dose 1–3 Gy: azoospermia possibly 
reversible
3–6 Gy: azoospermia possibly 
reversible (but unlikely)
6 Gy or more: azoospermia 
probably permanent
Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Alkylating agents and radiotherapy 
exposing testes
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Unilateral orchiectomy and radiotherapy 
exposing testes or alkylating agents
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Bilateral orchiectomy‡ Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Which surveillance modality should be used?
Tanner staging Yes Yes Yes Yes Concordant
Testicular volume Yes Yes Yes Yes Concordant
FSH Yes Yes Yes Yes Concordant
Inhibin B Not speciﬁ ed Not speciﬁ ed Yes Not speciﬁ ed Discordant
Semen analysis Yes Yes Yes Yes Concordant
At what frequency should impaired spermatogenesis surveillance be performed?
Tanner staging Every 1 year (until sexually 
mature)
Every visit Every 0·5 year 
(all survivors, until 
sexually mature)
Not speciﬁ ed Discordant
Testicular volume Every 1 year Every visit Every 0·5 year 
(all survivors)
Not speciﬁ ed Discordant
FSH In sexually mature patients if 
unable to obtain semen analysis
As clinically 
indicated
Every 0·5–1 years Not speciﬁ ed Discordant
Inhibin B N/A N/A Every 0·5–1 years 
(if available)
N/A N/A
Semen analysis As requested by patient As clinically 
indicated
When appropriate Not speciﬁ ed Partly 
concordant
What should be done when abnormalities are identiﬁ ed?
Refer to specialist Yes Yes Yes Yes Concordant
Consider assisted reproductive technology Yes (by consultation) Not speciﬁ ed Yes Yes Discordant
MOPP=mustargen (chlormethine, nitrogen mustard), oncovin (vincristine), procarbazine, prednisone. HSCT=haematopoietic stem cell transplant. FSH=follicle-stimulating 
hormone. *Busulfan, chlorambucil, cyclophosphamide, ifosfamide, chlormethine (nitrogen mustard), melphalan, thiotepa, carmustine, lomustine. †Radiotherapy potentially 
exposing the testes: whole abdomen, pelvic, testicular, prostate, ﬂ ank or hemiabdomen (if extended below iliac crest), inverted Y (para-aortic, iliac, inguinal, and upper 
femoral lymph nodes, often with spleen or splenic pedicle), bladder, iliac, inguinal, femoral, total lymphoid irradiation, total body irradiation. ‡Not for screening purposes; 
refer to endocrinology at 11 years of age for initiation of hormonal replacement therapy to induce puberty. 
Table 1: Concordance and discordance among impaired spermatogenesis surveillance recommendations
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spermatogenesis (level C evidence).29,30 Higher doses 
had greater risks than did lower doses (levels B 
and C).29–31 However, one study30 suggested that higher 
dacarbazine doses were no more toxic to 
spermatogenesis than lower doses (level C) but no 
studies compared patients who received or did not 
receive dacarbazine. No studies evaluated impaired 
spermatogenesis risk after treatment with other 
alkylating agents, platinum agents, or cytarabine.
Only weak evidence from the systematic search showed 
that TBI was associated with increased impaired 
spermatogenesis risk (level C).32 No studies compared 










Who needs testosterone deﬁ ciency surveillance?
At risk All survivors
Alkylating agents* Yes Not speciﬁ ed Yes Yes Discordant
Procarbazine Yes Not speciﬁ ed Yes Not speciﬁ ed Discordant
Temozolamide, dacarbazine Yes Not speciﬁ ed Yes Not speciﬁ ed Discordant
Carboplatin, cisplatin Yes Not speciﬁ ed Yes Not speciﬁ ed Discordant
Cytarabine Not speciﬁ ed Not speciﬁ ed Yes Not speciﬁ ed Discordant
Radiotherapy exposing testes† Yes if 20 Gy or more Not speciﬁ ed Yes Yes Discordant
Unilateral orchiectomy Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Highest risk
Higher doses alkylating agents Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Alkylating agent dose MOPP
Cyclophosphamide (≥20 g/m²) 
Cyclophosphamide for HSCT 
Ifosfamide (≥60 g/m²)
Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Combination alkylating agents Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Higher doses radiotherapy 
exposing testes
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Radiotherapy dose 20 Gy or more Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Radiotherapy exposing testis Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Alkylating agents and 
radiotherapy exposing testes
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Bilateral orchiectomy‡ Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Which surveillance modality should be used?
Height and weight Not speciﬁ ed Yes Yes Yes Discordant
Testicular volume Yes Yes Yes Yes Concordant
LH Not speciﬁ ed Yes Yes Yes Discordant
Testosterone Yes Yes Yes Yes Concordant
At what frequency should testosterone deﬁ ciency surveillance be performed?
Tanner staging Every 1 year (until sexually mature) Every visit Every 0·5 year (all 
survivors, until 
sexually mature)
Not speciﬁ ed Discordant
Testicular volume Every 1 year Every visit Every 0·5 year (all 
survivors)
Not speciﬁ ed Discordant
LH N/A As clinically 
indicated
Every 0·5–1 years Not speciﬁ ed Discordant
Testosterone Baseline at age 14 years and as 
clinically indicated (ideally morning)
As clinically 
indicated
Every 0·5–1 years Not speciﬁ ed Discordant
What should be done when abnormalities are identiﬁ ed?
Refer to specialist Yes Yes Yes Yes Concordant
Consider assisted reproductive 
technology
Not speciﬁ ed Not speciﬁ ed Yes Yes Discordant
MOPP=mustargen (chlormethine, nitrogen mustard), oncovin (vincristine), procarbazine, prednisone. HSCT=haematopoietic stem cell transplant. LH=luteinising hormone. 
*Busulfan, chlorambucil, cyclophosphamide, ifosfamide, chlormethine, melphalan, thiotepa, carmustine, lomustine. †Radiotherapy potentially exposing the testes: whole 
abdomen, pelvic, testicular, prostate, ﬂ ank or hemi-abdomen (if extended below iliac crest), inverted Y (para-aortic, iliac, inguinal, and upper femoral lymph nodes, often with 
spleen or splenic pedicle), bladder, iliac, inguinal, femoral, total lymphoid irradiation, total body irradiation. ‡Not for screening purposes; refer to endocrinology at 11 years of 
age for initiation of hormonal replacement therapy to induce puberty. 
Table 2: Concordance and discordance among testosterone deﬁ ciency surveillance recommendations
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diﬀ erent testicular radiotherapy doses, or evaluated risk 
after unilateral orchiectomy.
In the supplemental search, we identiﬁ ed several 
studies with important limitations (in terms of failing to 
meet all the inclusion criteria), but still reﬂ ecting expert 
opinion (appendix pp 49–53 for references). It was agreed 
that an increased risk of impaired spermatogenesis 
probably exists after treatment with busulfan and 
cyclophosphamide, or ﬂ udarabine and melphalan, 
haematopoietic stem-cell transplant (HSCT) conditioning, 
ifosfamide doses of more than 60 g/m², radiotherapy 
potentially exposing testes to more than 2–3 Gy, and TBI. 
Transient impairment of spermato genesis is expected 
and permanent impairment has been reported after 
radiotherapy treatment potentially exposing testes to less 
than 2–3 Gy, but there is probably not a substantially 
increased risk after these small doses, or after unilateral 
orchiectomy. The risks of impaired spermatogenesis after 
treatment with cisplatin are unclear.
The panel recommended that survivors treated with one 
or more potentially gonadotoxic agents should be advised 
of, and counselled about, the risk of impaired sperm-
atogenesis and its implications for future fertility (strong 
recommendations; level C evidence, supplemental search 
and expert opinion). Agents with potential to impair 
spermatogenesis include cyclophosphamide, chlor-
methine, and procarbazine (level C), ifosfamide, busulfan/
cyclophosphamide or ﬂ udarabine/melphalan, HSCT 
conditioning, and radiotherapy potentially exposing the 
testes (supplemental search and expert opinion). Because 
of interpatient variability and insuﬃ  cient evidence, it is 
not possible to make recommendations regarding risk-
stratiﬁ ed surveillance strategies based on either dose 
thresholds or age at treatment.
Which surveillance modality should be used?
The existing surveillance recommendations were concor-
dant in stating that Tanner stage33,34 and testicular volume, 
serum FSH, and semen analysis should be evaluated, 
but discordant for serum inhibin B measurement.
We found three studies7,35,36 that investigated the 
diagnostic value of serum FSH and inhibin B 










Who needs physical sexual dysfunction surveillance?
At risk
Neurosurgery spinal cord Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Pelvic surgery Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Cystectomy Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Radiotherapy exposing bladder, 
pelvis, spine
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Hypogonadism Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Tumour adjacent to spine Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Radical prostatectomy Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Retroperitoneal tumour resection or 
node dissection
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Highest risk
Higher doses radiotherapy Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Radiotherapy dose 55 Gy or more to penile 
bulb in adults
45 Gy or more in 
prepubertal children
Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Injury above level of sacrum Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Which surveillance modality should be used?
Sexual function (erections, nocturnal 
emissions, libido)
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Medication use impacting sexual 
function
Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Quality of ejaculate Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
At what frequency should physical sexual dysfunction surveillance be performed?
Sexual function Every 1 year Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Medication use Every 1 year Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Quality of ejaculate Every 1 year Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
What should be done when abnormalities are identiﬁ ed?
Refer to specialist Yes Not speciﬁ ed Not speciﬁ ed Not speciﬁ ed Discordant
Table 3: Concordance and discordance among physical sexual dysfunction surveillance recommendations
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concentrations in detecting azoospermia, one study for 
excluding azoospermia,37 and one for detecting 
oligospermia (deﬁ ned as <20 × 10⁶/mL).38 One study32 
evaluated the diagnostic value of serum FSH for 
excluding azoospermia. Two studies35,36 also investigated 
the diagnostic value of the combination of serum inhibin 
B and FSH for detecting azoospermia and one for 
detecting oligospermia.38 The results are summarised in 
the appendix (pp 43–45). AUCs of the ROC curve are 
approximately 0·7–0·8, suggesting that measurements 
of FSH, inhibin B, and inhibin B to FSH ratio all have 
fair diagnostic value for detecting azoospermia (level B 
evidence for FSH and inhibin B, level C for inhibin B to 
FSH ratio).
The panel recommended that for survivors who desire 
assessment about possible future fertility after treatment 
with potentially gonadotoxic therapy, semen analysis 
should be the gold standard as the primary surveillance 
modality for evaluating spermatogenesis (strong 
recommendation; expert opinion).
Clinical measurement of testicular volume, serum 
FSH, and inhibin B might be reasonable tests for 
identifying impaired spermatogenesis in survivors 
treated with potentially gonadotoxic therapy in whom 
semen analysis has been declined or is not possible, and 
who desire assessment about their possible future 
fertility (weak recommendation; level B evidence). 
However, it is important to be aware of the diagnostic 
limitations of these tests (appendix pp 25–29, 39–41).
At what frequency and for how long should surveillance be 
performed?
The existing surveillance recommendations are 
discordant regarding the frequency and duration of 
surveillance for impaired spermatogenesis, except for 
partial concordance regarding semen analysis.
No studies were identiﬁ ed that provided information 
about the probability, rate, or timing of changes 
(improvement or deterioration) in spermatogenesis 
parameters in male survivors treated with potentially 
gonadotoxic therapy.
The panel recommended surveillance for impaired 
spermatogenesis be performed only at the request of the 
survivor after informed discussion or when paternity is 
desired in the foreseeable future (strong recommendation; 
expert opinion).
When should survivors be referred?
The existing surveillance recommendations are concor-
dant regarding the timing of referral for impaired 
spermatogenesis but discordant regarding situations in 
which assisted reproductive technologies should be 
considered. A literature search was not performed 
because we considered that expert opinion allowed 
formulation of a pragmatic referral recommendation.
It is recommended that referral to a male reproductive 
health specialist should be oﬀ ered to survivors with 
severe oligozoospermia (sperm counts ≤5 × 10⁶/mL), to 
individuals seeking paternity after potentially gonadotoxic 
therapy, or to survivors whose attempts to conceive have 
been unsuccessful for 6 months or more,39 regardless of 
sperm count, for detailed specialist counselling or 
consideration of sperm cryopreservation if not already 
performed (strong recommendation; expert opinion).
Testosterone deﬁ ciency
The clinical presentation of testosterone deﬁ ciency varies 
with the age at onset. In prepubertal and peripubertal 
males, testosterone deﬁ ciency causes delayed or arrested 
puberty, respectively. In postpubertal males, testosterone 
deﬁ ciency leads to reduced sexual function and 
numerous systemic consequences including fatigue and 
increased cardiovascular risk.40
Who needs surveillance?
The existing surveillance recommendations were 
discordant with respect to which chemotherapy, radio-
therapy, and surgery exposures place CAYA cancer 
survivors at risk of testosterone deﬁ ciency.
In the systematic search, two studies41,42 revealed 
no increased risk of testosterone deﬁ ciency after cyclophos-
phamide treatment (level C evidence); one study42 also 
found no increased risk after procarbazine or platinum 
agents (level C). Another study43 found no increased risk 
after higher chlorambucil (672 mg/m²) and procarbazine 
(11 200 mg/m²) doses, compared with lower doses (504 and 
8400 mg/m²; level C). No studies compared diﬀ erent 
cyclophosphamide or platinum agent doses. No studies 
investigated risk after other alkylating agents or cytarabine.
One study42 found no increased testosterone deﬁ ciency 
risk after radiotherapy potentially exposing the testes 
(pelvic or abdominal, or TBI, doses not speciﬁ ed; level C). 
No studies were identiﬁ ed that addressed risk after 
diﬀ erent radiotherapy doses, or after unilateral 
orchiectomy.
One multivariable study42 showed that age at treatment 
had no eﬀ ect on testosterone deﬁ ciency risk, although 
only a minority of survivors had received radiotherapy 
potentially exposing the testes (level C).
In the supplemental search, several studies with 
important limitations (in terms of failing to meet all 
inclusion criteria), but reﬂ ecting expert opinion, were 
identiﬁ ed (appendix pp 49–53 for references). An increased 
risk of testosterone deﬁ ciency is probable after radiotherapy 
treatment that potentially exposes the testes to more than 
12 Gy of radiation or with TBI (7·5–15 Gy). An increased 
risk of testosterone deﬁ ciency is unlikely after radiotherapy 
potentially exposing testes to less than 12 Gy. According to 
this evidence and comparability with contemporary TBI 
schedules, a consensus was reached within the group that 
a testicular radiotherapy dose threshold of 12 Gy or more, 
or TBI, is probably associated with increased risk.
An increased risk after treatment with cyclophos-
phamide, busulfan and cyclophosphamide, or ﬂ udarabine 
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and melphalan, HSCT conditioning, procarbazine and 
chlormethine, ifosfamide, and cisplatin is probable.
The panel recommended that survivors treated with a 
potentially gonadotoxic agent should be advised of, and 
counselled about, the risk of testosterone deﬁ ciency and 
its implications for future health and fertility (strong 
recommendations; supplemental search or expert 
opinion). Treatments with the potential to cause 
testosterone deﬁ ciency include radiotherapy potentially 
exposing the testes to 12 Gy or more, and TBI (supple-
mental search or expert opinion). No recommendation 
can be made regarding risk-stratiﬁ ed surveillance 
strategies based on age at treatment.
Which surveillance modality should be used, at what frequency, 
and for how long?
The existing surveillance recommendations for 
testosterone deﬁ ciency are concordant in stating that 
Tanner stage and testicular volume should be evaluated, 
and serum testosterone and LH concentration measured. 
They are partially concordant for measuring height and 
weight, recommended for all survivors by the CCLG, 
DCOG, and SIGN guidelines but only for detecting 
precocious puberty by the COG guidelines. They are 
discordant regarding the frequency and duration of 
surveillance.
No studies were identiﬁ ed in the systematic or 
supplemental searches regarding the diagnostic value of 
single, compared with serial, serum LH or testosterone 
measurements to detect testosterone deﬁ ciency in 
postpubertal male survivors treated with potentially 
gonadotoxic therapy. Similarly, no studies were identiﬁ ed 
that provided information about the probability, rate, or 
timing of changes (improvement or deterioration) in 
testosterone deﬁ ciency.
The clinical presentation of testosterone deﬁ ciency in 
CAYA cancer survivors depends on age and can include 
delayed or arrested puberty, or a variety of clinical 
manifestations in postpubertal males. The following 
recommendations describe surveillance for each 
scenario.
Monitoring of growth (height) and pubertal 
development and progression (Tanner stage, testicular 
volume) is recommended for prepubertal and peri-
pubertal cancer survivors treated with radiotherapy 
potentially exposing testes to 12 Gy or more, or with TBI 
(strong recommendation; expert opinion). This moni-
toring should commence at no later than 12 years of age 
and should be performed at least annually, with 
increasing frequency as clinically indicated depending 
on growth and pubertal progress. In survivors who 
received cranial radiation, it should be noted that the 
pubertal increase in growth velocity may be impaired if 
growth hormone deﬁ ciency is also present.
Measurement of total testosterone concentration in an 
early morning blood sample at clinically appropriate 
intervals is reasonable in postpubertal survivors treated 
with radiotherapy potentially exposing the testes to 12 Gy 
or more, or with TBI (moderate recommendation; expert 
opinion). In the presence of clinical signs of hypo-
gonadism, previous low-normal or borderline 
testosterone concentrations, or in cases whereby it is not 
possible to obtain an early morning blood sample, 
measurement of LH concentration is reasonable in 
addition to testosterone (moderate recommendation; 
expert opinion).
When should survivors be referred?
The existing surveillance recommendations are concordant 
regarding the timing of referral for testosterone deﬁ ciency. 
A literature search was not performed because we 
considered that expert opinion allowed formulation of a 
pragmatic referral recommendation.
Referral to a paediatric endocrinologist is recommended 
for any male survivor who has no signs of puberty by 
14 years of age, or who shows failure of pubertal 
progression (strong recommendation; expert opinion).
Referral to a specialist in male reproductive health, 
andrology, endocrinology, or urology (depending on local 
referral pathways) is recommended for postpubertal 
male survivors treated with radiotherapy potentially 
exposing the testes to 12 Gy or more, or with TBI, and in 
whom laboratory results (reduced serum testosterone or 
increased serum LH concentration) suggest testosterone 
deﬁ ciency (strong recommendation; expert opinion).
Physical sexual dysfunction
Who needs surveillance?
The existing surveillance recommendations were 
discordant with respect to which chemotherapy, 
radiotherapy, and surgery exposures place CAYA cancer 
survivors at risk of physical sexual dysfunction.
The systematic search identiﬁ ed no studies reporting 
on risks for treatment-related physical sexual dysfunction 
after childhood cancer. The supplemental search 
identiﬁ ed several studies with important limitations (in 
terms of failing to meet all inclusion criteria), but 
reﬂ ecting expert opinion, were identiﬁ ed (appendix 
pp 49–53 for references). These studies suggested that 
hypogonadism (ie, decreased serum testosterone) is 
probably associated with an increased risk of sexual 
dysfunction. Surgery to the spinal cord, sympathetic 
nerves or pelvis, or radiotherapy potentially exposing the 
testes or pelvis, are probably each associated with an 
increased risk of sexual dysfunction.
The panel recommended that survivors treated with 
one or more treatment modalities with the potential to 
cause physical sexual dysfunction should be advised of, 
and counselled about, the risk of such dysfunction and 
its implications for future health and fertility (strong 
recommendation; supplemental search and expert 
opinion). Treatments with potential to cause physical 
sexual dysfunction include surgery to the spinal cord, 
sympathetic nerves or pelvis, radiotherapy potentially 
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exposing the testes or pelvis, or any treatment that 
causes hypogonadism (supplemental search and expert 
opinion).
Which surveillance modality should be used?
The existing surveillance recommendations are 
discordant regarding surveillance modalities for physical 
sexual dysfunction. We did not perform a search as 
clinical history is the only available surveillance tool.
It is recommended that health-care providers should 
take a relevant sexual history in postpubertal survivors 
treated with surgery to the spinal cord, sympathetic nerves 
or pelvis, or radiotherapy potentially exposing the testes or 
pelvis, or individuals who have been diagnosed with 
hypogonadism (strong recommendation; expert opinion).
It is not possible to formulate any recommendations 
about the frequency or duration of surveillance for 
physical sexual dysfunction in survivors.
When should survivors be referred?
The existing surveillance recommendations are 
discordant for the timing of referral for physical sexual 
dysfunction . A literature search was not performed 
because we considered that expert opinion allowed 
formulation of a pragmatic referral recommendation.
The panel recommended referral to a specialist in male 
reproductive health, andrology, endocrinology, or urology 
(according to local referral pathways) for survivors treated 
with surgery to the spinal cord, sympathetic nerves or 
pelvis, or radiotherapy potentially exposing the testes or 
pelvis, or those who have hypogonadism, and have 
symptoms suggestive of physical sexual dysfunction 
(strong recommendation; expert opinion).
Discussion
We present the international harmonised surveillance 
recommendations for gonadal dysfunction in male CAYA 
cancer survivors. Table 4 summarises the conclusions of 
the evidence from both the systematic and supplemental 
searches. Figure 2 presents the ﬁ nal recommendations 
and the panel presents the gaps in knowledge and future 
directions for research. The recommendations were 
derived from critical analysis of the published literature, 
using strict standards to grade supporting evidence, 
supplemented by expert consensus in areas in which 
little or no evidence was available.
Few published studies performing semen analysis or 
measuring serum testosterone in male CAYA cancer 
survivors were identiﬁ ed by our systematic search. 
Additionally, many studies did not mention whether 
testosterone was measured in early morning samples, 
limiting their utility. The search provided clear evidence 
for the gonadotoxicity of some modalities used in the 
treatment of CAYA cancer, but did not provide evidence 
for several other modalities that are widely believed to 
cause impaired spermatogenesis or testosterone 
deﬁ ciency (eg, radiotherapy exposing the testes). Evidence 
for associations between certain treatment modalities and 
impaired spermatogenesis or testosterone deﬁ ciency 
derives from studies that did not evaluate the primary 
outcomes (semen analysis, serum testosterone), were 
performed in other populations (eg, adults >25 years), 
included less than 20 patients, did not use statistical 
analyses that accounted for confounding factors, or 
predated 1993, and hence did not meet the systematic 
search’s inclusion criteria. Although many older 
publications (pre-1993) provide important insights, most 
did not evaluate the primary outcomes chosen or account 
for confounding factors. In view of the importance of the 
additional evidence that is available from the literature 
that did not meet the inclusion criteria, we performed a 
further supplemental search to evaluate this evidence in 
more detail. For some questions, the supplemental search 
provided data concerning risks and dose thresholds for 
toxicity of chemotherapeutic agents and testicular 
radiotherapy, optimising identiﬁ cation of treatments with 
or without evidence of probable gonadotoxicity, and 
assisting formulation of our recommendations. To ensure 
transparency of the guide line development process, the 
results of the systematic and supplemental searches are 
presented separately, and their contributions to the 
recommendations stated clearly.
The systematic search provided evidence for adverse 
eﬀ ects of cyclophosphamide, chlormethine and 
procarbazine on spermatogenesis, whereas the 
supplemental search demonstrated evidence for the 
probable toxicity of busulfan and cyclophosphamide, or 
ﬂ udarabine and melphalan combinations, and ifosfamide. 
Longstanding clinical experience has shown that 
testicular radiotherapy impairs spermatogenesis.6,44 The 
supplemental search provided evidence to support this 
observation from several sources including univariable 
studies, studies employing outcomes other than semen 
analysis (eg, FSH), or performed in adult cancer survivors. 
Although one study32 found no increased risk of impaired 
spermatogenesis after TBI on multivariable regression 
analysis, the comparator (non-TBI) group included 
individuals given other potentially gonadotoxic treatments 
including cyclophosphamide and busulfan. Therefore, 
for TBI, greater emphasis was placed on the results of the 
supplemental search. We identiﬁ ed no evidence that age 
at exposure inﬂ uences susceptibility to impaired 
spermatogenesis, thus it appears reasonable to extrapolate 
evidence from adult studies.
Risk factor evaluation for impaired spermatogenesis, 
particularly exposure to speciﬁ c treatment agents, is 
problematic. Potentially gonadotoxic drugs are frequently 
used in combination chemotherapy regimens and can 
also be used with radiotherapy potentially exposing the 
testes, sometimes with uncertain dosimetry. Many 
studies are small, retrospective, use varied doses, and do 
not allow for confounding factors. Alkylating agents used 
in combination are considered to have an additive 
adverse eﬀ ect on spermatogenesis.6 Time since treatment 




Impaired spermatogenesis risk* in CAYA cancer survivors Evidence from systematic search
Increased risk after cyclophosphamide vs no cyclophosphamide Level C29
Increased risk after higher cyclophosphamide dose vs lower dose Level B29,31
Increased risk after chlormethine vs no chlormethine† Level C30
Increased risk after higher chlormethine dose vs lower dose Level C30
Increased risk after procarbazine vs no procarbazine‡ Level C30
Increased risk after higher procarbazine dose vs lower dose Level C30
Risk after dacarbazine vs no dacarbazine No studies
No increased risk after higher dacarbazine dose vs lower dose Level C30
Risk after temozolomide No studies
Risk after other alkylating agents§ No studies
Risk after platinating agents¶ No studies
Risk after cytarabine No studies
No increased risk after radiotherapy potentially exposing the testes given as TBI vs no radiotherapy Level C32
Risk after higher dose of radiotherapy potentially exposing the testes vs lower dose No studies
Risk after unilateral orchiectomy No studies
Impaired spermatogenesis risk* in cancer survivors Evidence from supplemental search
Increased risk probable after busulfan and cyclophosphamide for HSCT Expert opinion||
Increased risk probable after ﬂ udarabine and melphalan for HSCT Expert opinion||
Increased risk probable after ifosfamide (>60 g/m²) Expert opinion||
Unclear risk after cisplatin Expert opinion||
Probably no increased risk after radiotherapy potentially exposing the testes to less than 2–3 Gy Expert opinion||
Increased risk probable after radiotherapy potentially exposing the testes to more than 2–3 Gy Expert opinion||
Increased risk probable after radiotherapy potentially exposing the testes given as TBI Expert opinion||
Probably no increased risk after unilateral orchiectomy Expert opinion||
Diagnostic value endocrine measurement to detect impaired spermatogenesis in CAYA cancer survivors Evidence from systematic search
Fair diagnostic value of inhibin B to detect azoospermia Level B7,35–37
Fair diagnostic value of FSH to detect azoospermia Level B7,32,35–37
Fair diagnostic value of inhibin B to FSH ratio to detect azoospermia Level C35
Impaired spermatogenesis risk in CAYA cancer survivors Evidence from systematic and supplemental 
searches
Likelihood or timing of changes (deterioration or improvement) in spermatogenesis parameters No studies
Testosterone deﬁ ciency
Testosterone deﬁ ciency risk in CAYA cancer survivors Evidence from systematic search
No increased risk after cyclophosphamide vs no cyclophosphamide Level C41,42
Risk after higher cyclophosphamide dose vs lower dose No studies
Risk after chlorambucil vs no chlorambucil No studies
No increased risk after higher chlorambucil dose vs lower dose† Level C43
No increased risk after procarbazine vs no procarbazine Level C42
No increased risk after higher procarbazine dose vs lower dose** Level C43
Risk after dacarbazine No studies
Risk after temozolomide No studies
Risk after other alkylating agents†† No studies
No increased risk after platinating agents¶ vs no platinating agents Level C43
Risk after higher platinating agents¶ dose vs lower dose No studies
Risk after cytarabine No studies
No increased risk after radiotherapy potentially exposing the testes given as TBI or pelvic or abdominal 
radiotherapy vs no radiotherapy
Level C43
Risk after higher dose of radiotherapy potentially exposing the testes vs lower dose No studies
Risk after unilateral orchiectomy No studies
(Table 4 continues on next page)
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may be another important variable given evidence of 
variable fertility or even late recovery of spermatogenesis 
during prolonged follow-up in some survivors.45–49 Even 
when these factors are controlled in studies whereby 
patients have received the same treatment exposures and 
have similar follow-up durations, interindividual 
diﬀ erences in vulnerability persist, possibly reﬂ ecting 
genetic inﬂ uences.31,50
Several studies have suggested an association between 
alkylating agent dose and the probability of impaired 
spermatogenesis.31 Additionally, a 2016 study51 found an 
association between higher cyclophosphamide, 
ifosfamide, procarbazine, and cisplatin doses and 
reduced probability of siring a pregnancy. However, 
although uncommon, azoospemia and oligozoospermia 
can occur after cyclophosphamide equivalent doses of 
less than 4000 mg/m²,31 and it has not been possible to 
establish a completely safe lower dose threshold.5,50 
Although the supplemental study suggested that 
testicular radiotherapy doses of more than 2–3 Gy are 
probably associated with a substantially increased risk of 
chronic spermatogeniesis impairment, whereas lower 
doses are unlikely to be associated with an increased risk, 
it is well known that even very small doses invariably 
cause acute impairment and that recovery does not 
always occur.44,52 Given this variability and the diﬃ  culty of 
excluding toxicity even with small doses, we concluded 
that any dose of potentially gonadotoxic alkylating agents 
or testicular radiotherapy should be regarded as possibly 
increasing the risk of impaired spermatogenesis.
Although the systematic search did not reveal evidence 
that alkylating agents, or radiotherapy potentially exposing 
the testes, are associated with an increased risk of 
testosterone deﬁ ciency, the supplemental search identiﬁ ed 
several studies suggesting that testicular radiotherapy 
probably leads to increased risk. This eﬀ ect was observed 
in all studies describing testicular radiotherapy doses of 
21–24 Gy or more and most studies evaluating doses of 
Evidence
(Continued from previous page)
Testosterone deﬁ ciency risk in cancer survivors Evidence from supplemental searches
Probably no increased risk after cyclophosphamide Expert opinion||
Probably no increased risk after busulfan and cyclophosphamide for HSCT Expert opinion||
Probably no increased risk after ﬂ udarabine and melphalan for HSCT Expert opinion||
Probably no increased risk after procarbazine and chlormethine Expert opinion||
Probably no increased risk after ifosfamide Expert opinion||
Probably no increased risk after cisplatin Expert opinion||
Probably no increased risk after radiotherapy potentially exposing the testes to less than 12 Gy Expert opinion||
Probably increased risk after radiotherapy potentially exposing the testes to 12 Gy or more Expert opinion||
Probably increased risk after radiotherapy potentially exposing the testes given as TBI Expert opinion||
Diagnostic value endocrine measurement to detect testosterone deﬁ ciency in CAYA cancer survivors Evidence from systematic and supplemental 
searches
Diagnostic value of luteinising hormone to detect testosterone deﬁ ciency No studies
Testosterone deﬁ ciency risk in CAYA cancer survivors Evidence from systematic and supplemental 
searches
Likelihood or timing of changes (deterioration or improvement) of testosterone levels No studies
Physical sexual dysfunction
Physical sexual dysfunction risk in CAYA cancer survivors Evidence from systematic search
Risk after surgery to the spinal cord, sympathetic nerves, or pelvis No studies
Risk after radiotherapy potentially exposing the testes or pelvis No studies
Risk in patients who are hypogonadal (decreased testosterone) No studies
Physical sexual dysfunction risk in cancer survivors Evidence from supplemental searches
Probably increased risk after surgery to the spinal cord, sympathetic nerves, or pelvis Expert opinion||
Probably increased risk after radiotherapy potentially exposing the testes or pelvis Expert opinion||
Probably increased risk in patients who are hypogonadal (decreased testosterone) Expert opinion||
For the key question ‘who needs surveillance’ we performed a supplemental literature search. We only performed and reported the supplemental search when there was no 
evidence available in the systematic search or if there was evidence not supporting an eﬀ ect. If there were no studies available we reported this as ‘no studies’. 
Level A=high level of evidence. Level B=moderate/low level of evidence. Level C=very low level of evidence. CAYA=childhood, adolescent, and young adult. TBI=total body 
irradiation. HSCT=haematopoietic stem cell transplant. FSH=follicle-stimulating hormone. *Refers to risk of permanently impaired spermatogenesis. †Given as part of multi-
agent treatment including procarbazine. ‡Given as part of multi-agent treatment including chlormethine. §Busulfan, chlorambucil, ifosfamide, melphalan, thiotepa, 
carmustine, lomustine. ¶Carboplatin, cisplatin. ||Expert opinion based on studies of the supplemental literature search that did not fulﬁ l the inclusion criteria or were of very 
low quality (appendix pp 49–53). **Given as part of multi-agent treatment including chlorambucil. ††Busulfan, chlormethine, ifosfamide, melphalan, thiotepa, carmustine, 
lomustine.
Table 4: Conclusions of evidence from the systematic and supplemental literature search* for gonadotoxicity surveillance for male CAYA cancer survivors
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Impaired spermatogenesis
General recommendation Survivors treated with one or more potentially gonadotoxic agents, and their health-care providers, should be aware of the risk of impaired 




Counselling regarding the risk of impaired spermatogenesis and its implications for future fertility is recommended for survivors treated with:
• Cyclophosphamide, chlormethine, procarbazine (level C evidence), busulfan and cyclophosphamide or ﬂudarabine and melphalan for haematopoietic 
 stem-cell transplant, ifosfamide (supplemental literature search and expert opinion)
• Radiotherapy potentially exposing testes (supplemental literature search and expert opinion)




Which surveillance modality should be
used?
In survivors who desire assessment about possible future fertility after treatment with potentially gonadotoxic chemotherapy or radiotherapy potentially 
exposing the testes,† semen analysis is recommended as the gold standard primary surveillance modality for evaluation of spermatogenesis (expert opinion)
Clinical measurement of testicular volume and of follicle-stimulating hormone and inhibin B might be reasonable for the identiﬁcation of impaired 
spermatogenesis in survivors treated with potentially gonadotoxic chemotherapy or radiotherapy potentially exposing the testes* in whom semen analysis 
has been declined or is not possible and who desire assessment about possible future fertility. Be aware of the diagnostic limitations of these tests that may 
result in false positives or false negatives (level B evidence)
At what frequency and for how long 
should surveillance be performed?
Surveillance for impaired spermatogenesis should be performed only at the request of the survivor after informed discussion or when paternity is desired 
in the foreseeable future (expert opinion)
When should survivors with impaired 
spermatogenesis be referred?
Referral to a male reproductive health specialist should be oﬀered to survivors with severely impaired spermatogenesis, deﬁned as severe oligospermia
(sperm counts ≤5 × 10⁶/mL), or to those who are seeking paternity after potentially gonadotoxic chemotherapy or radiotherapy potentially exposing the 
testes, and to those whose attempts to conceive have been unsuccessful for 6 months or more, regardless of sperm count, for detailed specialist counselling 
or consideration of sperm cryopreservation if not already performed (expert opinion)
Testosterone deficiency
Survivors treated with a potentially gonadotoxic agent, and their health-care providers, should be aware of the risk of testosterone deﬁciency and its 
implications for future health and fertility (supplemental literature search and expert opinion)
Counselling regarding the risk of testosterone deﬁciency and its implications for future health and fertility is recommended for survivors treated with  
radiotherapy potentially exposing the testes to 12 Gy or more or with total body irradiation (supplemental literature search and expert opinion)
Which surveillance modality should be 
used for prepubertal and peripubertal 
survivors? At what frequency and for 
how long?
Monitoring of growth (height) and pubertal development and progression (Tanner stage including testicular volume)†‡§ is recommended for prepubertal 
and peripubertal survivors treated with radiotherapy potentially exposing the testes to 12 Gy or more or with total body irradiation (expert opinion)
Which surveillance modality should 
be used for postpubertal survivors? 
At what frequency and for how long?
Measurement of testosterone concentration in an early morning blood sample at clinically appropriate intervals is reasonable in postpubertal survivors 
treated with radiotherapy potentially exposing the testes to 12 Gy or more or with TBI (expert opinion). In the presence of clinical signs of hypogonadism, 
or of previous low-normal or borderline testosterone concentrations, or if it is not possible to obtain an early morning blood sample, it is reasonable to 
measure luteinising hormone concentration in addition to testosterone (expert opinion)
When should survivors with abnormalities 
of pubertal development be referred?
Referral to a paediatric endocrinologist is recommended for any survivor who has no signs of puberty by 14 years of age or failure of pubertal progression¶ 
(expert opinion)
When should postpubertal survivors 
with suspected testosterone deficiency 
be referred??
Referral to a specialist in male reproductive health, andrology, endocrinology or urology (according to local referral pathways) is recommended for 
postpubertal survivors treated with radiotherapy potentially exposing the testes to 12 Gy or more or with TBI, and in whom laboratory results suggest 
testosterone deﬁciency (expert opinion)
Physical sexual dysfunction
Weak recommendation to do
Survivors treated with one or more treatment modalities with potential to cause physical sexual dysfunction, or those who are hypogonadal, and their
 health-care providers, should be aware of the risk of physical sexual dysfunction (including erectile and ejaculatory dysfunction) and its implications for 
future health and fertility (supplemental literature search and expert opinion)
Counselling regarding the risk of physical sexual dysfunction (including erectile and ejaculatory dysfunction) and its implications for future health and 
fertility is recommended for survivors (supplemental literature search and expert opinion):
•  Treated with surgery to the spinal cord, sympathetic nerves, or pelvis
•  Treated with radiotherapy potentially exposing testes or pelvis
•  Individuals who are hypogonadal 
Providers should take a relevant sexual history in survivors treated with surgery to the spinal cord, sympathetic nerves, or pelvis, or radiotherapy potentially 
exposing testes or pelvis, or those who are hypogonadal (expert opinion)
When should survivors with suspected 
physical sexual dysfunction be referred?
Referral to a specialist in male reproductive health, andrology, endocrinology, or urology (according to local referral pathways) is recommended for survivors 
treated with surgery to the spinal cord, sympathetic nerves, or pelvis, or radiotherapy potentially exposing testes or pelvis, or those who are hypogonadal, 
and  who have symptoms suggesting physical sexual dysfunction (expert opinion)
Strong recommendation to do Moderate recommendation to do
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12 Gy or more, including TBI. One study42 found that TBI 
was associated with a lower testosterone concentration 
compared with no TBI on univariable analysis, but not on 
multivariable analysis. However, the analyses in this study 
considered testosterone concentration as a continuous 
variable. Therefore, the ﬁ ndings of the supplemental 
search were considered to have greater relevance to this 
clinical question, allowing a conclusion to be made that 
testicular radiotherapy doses of 12 Gy or more are probably 
associated with an increased risk of testosterone deﬁ ciency.
The systematic search did not identify any studies that 
clariﬁ ed which survivors are at risk of physical sexual 
dysfunction, but the supplemental search found relevant 
evidence predominantly from studies of survivors of 
adult cancer or other patient populations, but reﬂ ecting 
clinical experience in CAYA cancer survivors. 
A 2016 study53 on erectile dysfunction in male childhood 
cancer survivors was published too late to be included in 
our systematic Review, although an abstract from the 
same group was included in our supplemental search.54 
Both publications described an increased risk of erectile 
dysfunction in survivors treated with higher dose 
(≥10 Gy) testicular radiotherapy, or surgery to the spinal 
cord or nerves, pelvis or prostate, when compared with 
their siblings. These sources of alternative evidence 
supported the conclusion that surgery to the spinal cord, 
sympathetic nerves or pelvis, radiotherapy potentially 
exposing the testes or pelvis, or any other treatment that 
causes hypogonadism, are each probably associated with 
an increased risk of physical sexual dysfunction.
A clear clinical and scientiﬁ c consensus that semen 
analysis represents the gold standard for evaluating 
spermatogenesis exists.55 However, some survivors might 
decline or be unable to provide semen for analysis, and 
single results can be misleading.55 Health-care providers 
should be aware that results indicating severely impaired 
spermatogenesis can cause considerable distress to 
survivors, who might require appropriate psychological 
support. The eﬀ ect of these results can be ameliorated by 
referral to a male reproductive health specialist to provide 
additional and more detailed counselling for the survivor, 
including information about future reproductive health 
options. This information can often provide some 
comfort for survivors.
Previously published long-term follow-up guidelines18–20 
have recommended measurement of testicular volume 
and serum FSH as surveillance. The DCOG guideline 
also recommended inhibin B measurement, particularly 
in the absence of semen analysis. A study30 in adult 
survivors of childhood Hodgkin lymphoma reported that 
only inhibin B showed an independent correlation with 
sperm concentration. Our results conﬁ rm that these 
measurements have fair diagnostic value for the 
detection of impaired spermatogenesis. Although 
testicular volume was not included as a clinical question, 
the studies identiﬁ ed conﬁ rmed that it has good 
diagnostic value (AUCs of ROC curves 0·7–0·9) in 
detecting oligozoospermia38 or excluding azoospermia.32,37 
Therefore, these measurements might be reasonable in 
survivors in whom semen analysis is not available and 
who desire assessment about future fertility potential. 
However, FSH and inhibin B have considerable 
limitations for surveillance because they can give false 
positive or false negative results. For example, one of the 
included studies35 found that 22% of survivors with 
azoospermia had a normal (ie, false negative) FSH result, 
whereas 26% of those without azoospermia had an 
abnormal (ie, false positive) result. Analysis of the 
inhibin B to FSH ratio did not improve this situation.35 
Therefore, clinical treatment and personal factors also 
need to be considered in individual survivors when 
judging whether or not to use these tests for surveillance.
No evidence was identiﬁ ed to inform recommendations 
regarding the frequency of surveillance for impaired 
spermatogenesis. This emphasises the importance of 
only undertaking such surveillance after informed 
discussion with survivors who desire paternity in 
the foreseeable future. The detection of severe oligozoo-
spermia in individuals without previously stored sperm 
might suggest that referral to a male reproductive health 
specialist is appropriate for consideration of sperm 
cryopreservation to maximise the prospect of success 
with future attempts at assisted reproduction.56 
Consideration of sperm cryopreservation might be 
particularly important for survivors who are about to 
begin testosterone therapy, which could impair 
spermatogenesis further.57 The rapid pace of advances in 
the ﬁ eld of male reproductive health, for example the use 
of surgical testicular sperm extraction followed by 
intracytoplasmic sperm injection,58 highlights the value 
of referral to a male reproductive health specialist even in 
azoospermic CAYA cancer survivors.
The recommendation for the surveillance modality for 
testosterone deﬁ ciency in postpubertal survivors is 
focused primarily on serum testosterone measurement, 
whilst maximising ﬂ exibility of clinical application by 
recommending measurement of LH in certain deﬁ ned 
situations. The 2014 publication59 of validated age-related 
normal values for total testosterone will facilitate early 
detection and appropriate referral of testosterone 
deﬁ ciency, hence enabling reduction of morbidity.60 
Figure 2: Harmonised recommendations for gonadotoxicity surveillance for 
male CAYA cancer survivors
*Treatments with evidence and expert opinion for causing impaired 
spermatogenesis include cyclophosphamide, chlormethine, procarbazine 
(level C evidence), busulfan and cyclophosphamide or ﬂ udarabine and 
melphalan for HSCT, ifosfamide, or radiotherapy potentially exposing the testes 
(supplemental literature search and expert opinion). †At least annually, with 
increasing frequency as clinically indicated depending on growth and pubertal 
progress. ‡Regular growth and pubertal monitoring should be started by no 
later than 12 years (and no earlier than 10 years) of age. §The pubertal increase 
in growth velocity may be impaired if growth hormone deﬁ ciency is also present 
in survivors who received cranial radiation. ¶The absence of initiation of puberty 
(Tanner stage 2) in boys aged 14 years or older or failure to progress in pubertal 
stage for 6 months or more. 
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Although testosterone deﬁ ciency can be diagnosed readily 
by ﬁ nding a low testosterone concentration in an early 
morning blood sample, the importance of borderline 
values might be uncertain. In such cases, serum LH 
concentration facilitates clinical evaluation. Surveillance 
might facilitate earlier detection of testosterone deﬁ ciency, 
which is important as the condition itself might lead to 
depression,12 and could reduce the probability of seeking 
medical consultation with (or even within) planned 
follow-up and surveillance. If testosterone deﬁ ciency is 
suspected, referral for specialist assessment is indicated 
because, although testosterone replacement treatment 
may be appropriate in deﬁ cient patients following 
accepted endocrine guidelines, the potential beneﬁ ts and 
risks of treatment need to be considered appropriately for 
each individual.40,61–65
Deﬁ nitions of failure of pubertal progression are not 
standardised, but our pragmatic recommendation to 
seek specialist referral following no advancement in 
Tanner stage over a 6-month period is intended to avoid 
delayed referral in a population of survivors at high risk 
of pubertal failure and consequent potential impairment 
of growth, metabolic health, bone mineral accretion, and 
quality of life as a result of testosterone deﬁ ciency.64
Several factors can inﬂ uence the decision to undertake 
surveillance investigations and subsequently to refer 
survivors for specialist opinion, including perceptions of 
the reliability and utility of surveillance investigations, 
complexities in their interpretation, eﬀ ects of the condition 
itself, treatments that could potentially be available to 
manage the condition, and possible treatment toxicities.
The task of harmonising male gonadal dysfunction 
surveillance guidelines was strengthened by our 
evidence-based approach with standardised outcome 
deﬁ nitions, transparent presentation of the quality of 
available evidence and the strength of recommendation, 
and the multidisciplinary approach necessary to achieve 
consensus. When evidence was scarce for CAYA cancer 
survivors, we carefully extrapolated information from 
other populations.
The process used in the development of this guideline 
has revealed several substantial knowledge gaps for 
clinical research that could improve surveillance of 
gonadotoxicity in male CAYA cancer survivors. Research 
to address these gaps should be approached in a 
systematic, comprehensive manner by suﬃ  ciently large 
single-institution studies, or national and international 
multicentre collaborative projects.
This male gonadotoxicity surveillance guideline, and 
the international harmonisation initiative that underpins 
it, aims to improve health outcomes by facilitating more 
consistent long-term follow-up care for current male 
CAYA cancer survivors and promote strategically planned 
ongoing research that will inform future guidelines 
updates.
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Panel: Gaps in knowledge and future directions for research
Impaired spermatogenesis or testosterone deﬁ ciency
• Risks of, and dose thresholds for, impaired spermatogenesis or testosterone deﬁ ciency 
in survivors treated with:
• Busulfan, chlorambucil, cyclophosphamide, ifosfamide, chlormethine, melphalan, 
and thiotepa (classical bifunctional alkylating agents)
• Dacarbazine, procarbazine, temozolomide (triazenes)
• Carboplatin, cisplatin (platinum agents)
• Carmustine, lomustine (nitrosoureas)
• Radiotherapy exposing the testes, including those treated with total body 
irradiation
(either alone or in combination)
• Inﬂ uence of cyclophosphamide equivalent dose (calculated from formula that 
incorporates cumulative doses of busulfan, carmustine, chlorambucil, 
cyclophosphamide, ifosfamide, lomustine, chlormethine, melphalan, procarbazine, 
and thiotepa) on risk of impaired spermatogenesis and testosterone deﬁ ciency in 
survivors
• Potential recovery or deterioration of spermatogenesis or testosterone deﬁ ciency over 
time after these treatments
• Eﬀ ect of age at treatment on the risk of impaired spermatogenesis or testosterone 
deﬁ ciency with any of the treatments listed above, risk of diﬀ erent cyclophosphamide 
equivalent doses, or potential recovery or deterioration
• Role of genetic susceptibility in thedevelopment of impaired spermatogenesis or 
testosterone deﬁ ciency in survivors treated with alkylating agents or radiotherapy 
exposing the testes
• Development of a risk prediction algorithm, taking into account demographic, 
treatment, and genetic variables, on risk of impaired spermatogenesis or testosterone 
deﬁ ciency in survivors
• Development of improved and more accessible biomarkers for impaired 
spermatogenesis or testosterone secretion
• Evaluation of potential psychological harm associated with excessive screening for 
impaired spermatogenesis, particularly from false positive results
• Diagnostic value of luteinising hormone to detect testosterone deﬁ ciency
• Evaluation of potential health beneﬁ ts associated with appropriate identiﬁ cation of 
testosterone deﬁ ciency
Physical sexual dysfunction
• Risk of physical sexual dysfunction in male survivors treated with:
• Surgery to the spinal cord, sympathetic nerves, or pelvis
• Radiotherapy potentially exposing the testes, pelvis, or male reproductive organs
• Evaluation of potential beneﬁ ts associated with appropriate identiﬁ cation of physical 
sexual dysfunction in male survivors
• Potential recovery or deterioration of physical sexual dysfunction in male survivors 
during lifespan 
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